“Little-known brain disease rips apart lives” (FTD)

This is a terrific article in today’s Los Angeles Times (latimes.com) about a family challenged by FTD (frontotemporal dementia), which used to be called Pick’s Disease.  In the local Brain Support Network group, we’ve had two people with a clinical diagnosis of PSP who were diagnosed with FTD (Pick’s Disease) upon brain autopsy.  Also, one person in our BSN support group was clinically diagnosed with DLB but ended up with a different type of frontotemporal dementia on brain autopsy.  So….it’s probably good for those dealing with dementia to know about FTD as it can look like the disorders in our group.

I do wish we could get some wonderful articles written about the disorders in our group in the SF Chronicle or SJ Mercury News!

Robin

***************************

latimes.com/news/local/la-me-dementia-20120210,0,5574998.story

COLUMN ONE
Little-known brain disease rips apart lives of victim, loved ones

By Thomas Curwen
Los Angeles Times
February 10, 2012

When Stu Bryant began acting rude and impulsive, his family was baffled. Then they learned he had frontotemporal disease, which strips away self-restraint and the ability to decipher social situations. More than a year after the diagnosis, Maureen Bryant had grown accustomed to making excuses for her husband. When Stu stood behind a tattooed woman in line at Panda Express, and said loudly, “Wow, that’s a lot of tattoos,” Moe stepped between him and the woman and apologized.

When he repeatedly wandered into the house that was being built down the street — despite the “No Trespassing” sign and the fence — she explained to the owner that he was just curious. Possibly the most embarrassing episode occurred when they were coming home from dinner, and she dashed into a mini-mart at a marina in Oxnard to buy milk.

 
Here’s a link to the full article:
latimes.com/news/local/la-me-dementia-20120210,0,5574998.story

“Different Forms of Dementia” including Lewy Body Dementia – webinar notes

The American Society on Aging (asaging.org) hosted a webinar on Monday, November 21st on the topic of “Understanding the Different Forms of Dementia.”  The speaker was Teepa Snow (teepasnow.com), a dementia education specialist.

Though I think Teepa Snow is typically an incredible presenter, the one-hour webinar format didn’t suit her.  She raced through the material, and didn’t cover many slides.  I thought her discussion of Alzheimer’s and mixed dementia were very good.  For Lewy Body Dementia, I think she would’ve done better by looking at the diagnostic criteria.  I thought she was very unclear on FTD (frontotemporal dementia).  And I think she under-rates the challenge of diagnosing dementia.

She said two things about Lewy Body Dementia that were new to me:
* “This is not AD plus PD.”
* “About 50% of those with LBD can’t get into REM sleep.”

You can find an online recording of the webinar here:
www.screencast.com/t/kwaagMKHNhy

Put your mouse over the “11-21-11” area.  Click on the file folder that appears below the word “Understanding.”

And, I’ve copied my notes from the webinar below.  (In some cases, I’ve combined my notes with Teepa Snow’s slides, particularly for the many slides that she didn’t cover in full.)

Robin

——————————

Robin’s Notes from

Understanding the Different Forms of Dementia
Speaker – Teepa Snow, a dementia education specialist
11/21/11 Webinar

Three sponsors =
Alzheimer’s Foundation of America (alzfdn.org)
Senior Helpers (seniorhelpers.com)
American Society on Aging (asaging.org)

Recording will be posted on asaging.org (American Society on Aging) within a week.

Learning objectives of this webinar:
* Distinguish the difference between normal and abnormal changes in brain functions associated with the aging process.
* Describe similarities and differences among dementia, delirium, and depression.
* Compare various dementias regarding initial symptoms, progression patterns, and management and treatment strategies.
* Discuss the importance of the role of the care partner in helping to effectively manage the care plan and treatment of individuals living with various dementias.

Dementia is caused by changes in the brain:
* Structural changes:  permanent; cells are shrinking and dying
* Chemical changes:  variable; cells are producing and sending less chemicals; people can “shine” when least expected (“chemical rush”)

“Dementia” – umbrella term that covers 70-80 different disorders, such as Alzheimer’s Disease (50-60%), vascular dementias, Lewy body dementia, fronto-temporal lobe dementias, other dementias.  The “other dementias” category includes genetic syndromes, drugs/toxin exposure, white matter diseases, and Parkinson’s.  Most of AD co-occurs with other dementias.  These are terminal disorders.  These are life-altering disorders.

ALZHEIMER’S

Alzheimer’s has two forms — young onset (used to be called “early onset”; younger than 65), and late onset (or “normal onset”; more common; after age 65; average onset is 75).  People in their 20s have AD!

Over 65, 5-10% of population has AD.  At 85, closer to 50% of population has AD.  Dramatic increase between 65 and 85!

With AD, brain shrinks by one-third.

PET scans of glucose activity by Gary Small, MD, at UCLA.  Most with “Early Alzheimer’s” don’t have an AD diagnosis.  Person and family might be aware of subtle changes.  Similarities in PET scans between 90 YO with late AD and a child!

Young onset AD:  genetics can be involved or lifestyle (high stress; sedentary; not socializing) can be involved.  Many have young families (children in the house).  Misdiagnosis (including psychiatric illnesses; mid-life crises; menopause; substance abuse) and non-diagnosis are common.  Work may be the first place to notice changes (may be fired).  Relationships are strained early.  Services can be a problem.  Finances are often problematic.

Down Syndrome:  beta-amyloid plaques are in the brain at birth; young onset.

Late onset AD:  New info is lost.  Recent memory worse.  Problems finding words.  Misspeaks.  More impulsive or indecisive.  Gets lost in time and place.  Notice changes over 6 months to 1 year.  Can last 8-12 years, on average.

VASCULAR DEMENTIA

Problems not due to disease.  Damage is related to blood supply, not primary brain disease.  White spots on CT scan indicate dead cell areas — mini-strokes.  Symptoms depend on where the dead areas are.

Sudden changes, known as stepwise progression.

Treatment can plateau.  Treatment involves managing vascular health.

Other conditions:  diabetes, hypertension, heart disease.

Picture varies by person (blood/swelling/recovery).

Can have bounce back and bad days.

Least-predictable of all the dementias.

Judgment and behavior is “not the same”

Spotty loss (memory, mobility).

Emotional and energy shifts.  Person is very labile:  go from one extreme to another pretty quickly.  Example:  ask someone “how are you doing?” and they start crying and say “I don’t know.”  Advice:  leave the room, come back with Kleenex.  This distraction solves problem.  Another situation is that the person is very apathetic.

Can last 3-30 years.

LEWY BODY DEMENTIA

Important to know about.  This is not AD plus PD.  This is a different phenomenon.

Most mis-diagnosed and missed as a diagnosis.

Can be misidentified as PD.  It does involve movement problems (especially frequent falls) early in the disease.  Often falls are in bathrooms and bedrooms.

Can have visual hallucinations.  Almost always involve animals, children, or people.  Usually in the late afternoon and evening.  Some people have insight into their hallucinations.

Can have fine motor problems — hands and swallowing.

Don’t often have rest tremor.  The person is often awkward due to an intention tremor.  (This is a distinguishing characteristic.)

Episodes of rigidity.  The person might get stuck.  They are NOT getting stuck on purpose!

Episodes of syncope.

Can have nightmares.  Think dreams are real.  Can have a dark edge of the dreams.

Can have insomnia.  About 50% of those with LBD can’t get into REM sleep.

Fixed delusional thinking.

Fluctuations in abilities.

Drug responses can be extreme and strange.  This is probably the most important thing.  Often, MDs, if they are thinking PD, will prescribe Sinemet.  Sinemet can make the hallucinations worse.  Often the drugs used to treat hallucinations are antipsychotics.  50% of those with LBD have a seriously strong reaction (extrapyramidal side effects) to antipsychotics.  This is one of the reasons for a black-box warning on antipsychotics.

Often drugs used to treat agitation can make the problem worse.

Average:  live 7-9 years with symptoms.

FRONTO-TEMPORAL DEMENTIAS

Many types:
* Frontal – loses impulse and behavior control (no memory issues).  Says unexpected, rude, mean, odd things to others.  Disinhibited with food, drink (so serious the person can get hyponatremia), sex, emotions, actions.  OCD-type behaviors.  Hyperorality.
* Temporal – language loss.  Cannot speak or get words out.  Cannot understand what is said.  Sounds fluent but using nonsense words.

Those with frontal lobe dementias:  can end up arrested.  Highest risk:  genetic and head injury.

“PPA (Primary Progressive Aphasia) Nonfluent” – older term for temporal dementia

Types:
* FvFTD – frontal variant of FTD
* FTD – frontal-temporal lobe dementia
* TLD – non-fluent aphasia
* TLD – fluent aphasia
[Robin’s note:  yes, those last two both say “TLD”]

Temporal Lobe Non-Fluent Aphasia:  very frustrating; locked-in dementia; cannot name items; hesitant speech; not speaking; worsening of speech production over time; echolalia; misspeaking; word salad; receptive inability; other skills intact — early; 25% never develop global dementia

Fluent Aphasia

FTD (Pick’s Disease)
* Frontal Issues:  poor decision making; problems sequencing; reduced social skills; lack of self-awareness; hyperorality; egocentric; disinhibited (food, drink, words, actions); OCD behaviors early; excessive emotions
* Temporal Issues:  reduced attempts to talk; reduced content in speech; poor volume control; public use of “forbidden words”; sing-song speech; cannot understand others’ words

OTHER DEMENTIAS

Could be atypical dementia, other dementia, or mixed dementia

40% of those with PD will develop dementia

Up to 50% of those with depression will develop dementia late in life.

Those with toxic exposure (drugs, heavy metals) or pesticide exposure can develop dementia

Other dementias:
* genetic syndromes:  Huntington’s Chorea
* ETOH related
* white matter diseases:  MS
* mass effects:  tumors and NPH
* infections that cross the blood brain barrier:  Creutzfeld-Jakob, HIV/Aids

Some progress very rapidly.  Some are unique while some follow more traditional patterns.

In a mixed picture, it is possible to:
* have multiple forms
* start with one and add another
* have some symptoms, but not all
* have other life-long issues and then develop dementia (Down syndrome, mental illness, personality disturbances, substance abuse)

SEEING A DOCTOR

If you begin to notice changes, what should you do?
* Get it assessed
* Go see the doctor!

Why see a doctor?
* Future plans:  progression and prognosis; finances; health
* Being in control
* Medications can make a difference in quality of life
* Get educated about the disease
* Take advantage of the right support services

Old screening option is the MMSE.  It’s short but helpful.

New screening options:
* AD8 interview
* SLUMS:  7 minute screen; short but helpful
* Animal fluency:  # of animals that can be named in one minute
* Clock drawing:  2 step
* Full neuropsychological testing panel
* Mini-Cog
* MIS
* GP-COG

AD8 dementia screening interview:
* Does your family member have problems with judgment?
* Does your family member show less interest in hobbies/activities?
* Does your family member repeat the same things over and over?
* Does your family member have trouble learning how to use a tool, appliance, or gadget?
* Does your family member forget the correct month or year?
* Does your family member have trouble handling complicated financial affairs?
* Does your family member have trouble remembering appointments?
* Does your family member have daily problems with thinking or memory?
AD8 score:  Changed, Not Changed, Don’t Know

If the screening identifies concern:
* Review current medications
* Complete work-up and follow up OR Send for a full neuropsychological evaluation
* Then, follow up with you OR Refer to a specialist

MIMICS OF DEMENTIA

Depression:  cannot think; cannot remember; not worth it; loss of function; mood swings; personality change; change in sleep

Delirium:  swift change; hallucinations; delusions; on and off response; infection; toxicity; dangerous

WHEN YOU NOTICE SOMETHING

* If person is aware and cooperative, partner and support
* If person is not aware and not interested or willing, look for authority figure to help.  Be willing to change how you talk about your concern.  Weigh the cost-benefit.  Ask for the person’s help FOR you….not about them.  Do you have a healthcare POA?

GETTING A DIAGNOSIS

What should happen?
* A complete physical, medical, and psychological history
* A good history from the person and the family of the situation
* A thorough PE neurological and cardiac exam with blood work
* A complete medication review
* Imaging study (CT, MRI, PET)
* Neuropsychological testing – what works and what does not
* Follow-up and counseling or at least a referral

When should you get a second opinion?
* When what we talked about did not happen
* When you feel un-listened to about concerns
* When you are not offered options that seem reasonable
* When you think or feel that the doctor is not skilled enough to do a good job of managing this
* When it is an atypical dementia

How you can help?
* Be supportive
* Be an advocate
* Work out healthcare support (HC-PoA)
* Check with your doctor – raise your concern
* Consider a neuropsychological assessment
* Consider seeing a specialist — geriatrician, neurologist, gero-psychiatrist

RESOURCES
* Alzheimer’s Foundation of America:  www.alzfdn.org
* Senior Helpers:  www.seniorhelpers.com
* American Society on Aging:  www.asaging.org
* Teepa Snow:  www.teepasnow.com

QUESTIONS & ANSWERS  (45:00)

Question:  How do we interact with someone with FTD?

Answer:  For frontal lobe dementia, the most important thing to know is that the person can be impulsive, and although the person may know they are not supposed to do something, they are still going to do it.  We need to quit creating opportunities where the impulse will create a bad outcome.

You can’t stand in front of the door and say “you can’t go out and drive,” as you will get hurt.  You want to remove the car keys from the immediate vicinity, and let someone else be the bad guy.

This person needs a controlled environment early on.

When someone is doing something, use positive social engagement.  Rely on automatic responses.

If it’s a temporal lobe problem, stop using so many words.  Slow down your speech.  Don’t get too close.  Don’t put your hands on them.  Repeat a few of the words they said.

If it’s a fluent aphasia, go along with their speech.

If it’s a nonfluent aphasia, say:  “You are a very smart person.  I’m so sorry but I can’t understand what you are saying.”  Don’t say “It’s OK, it’s OK.”

Q:  Meds for AD?

A:  AChEIs (Aricept, Exelon, Razadyne) – help with symptom management.  Don’t help with the disease.  Helps brain produce more acetylcholine in some people.  Can only help living cells.  Most effective early in the disease.  Late in the disease, acetylcholine may be helping your brain to remember to put food in your mouth and chew.  We don’t know when this medication becomes ineffective.  It’s not for everyone.  Always consider giving it a dry.  These drugs are for AD, but not necessarily for FTD.

There’s also Namenda.  Controls glutamate in brain.  Can keep brain on an even keel.

We don’t know if people are short on acetylcholine and need to have their glutamate level moderated.  Must weigh downsides (GI, may bother heart, may bother gut).

Q:  Tool to tell difference between these conditions?

A:  What were the very first symptoms anyone noticed?  The first symptoms tell us where the disease started.  Where the disease started is important.  This helps identify the primary dementia.

Upon brain autopsy, for those cases where we got a really good history, 90% of the time we are accurate.

Key indicators:
AD – memory; immediate recall
LBD – movement; hallucinations; delusional thinking
FTD – behaviors or language
Benson’s – visual processing (we haven’t talked about this one)

Q:  We are seeing more LBD and vascular dementia diagnoses these days.  Is the frequency increasing?

A:  We are diagnosing people better.

For the first time, Alzheimer’s is no longer a diagnosis of exclusion.

Mayo Clinic research on forms of Alzheimer’s, including hippocampal sparing

One of Brain Support Network’s missions is to assist families around the United States with brain donation.  We have helped over 100 families donate a loved one’s brain.  Half of the confirmed diagnoses are different from the clinical diagnoses! We often see one diagnosis “wrong” more often than others – corticobasal degeneration. Often, those with supposed CBD have an atypical form of Alzheimer’s confirmed through brain donation.  And we sometimes see the same pattern in frontotemporal dementia (FTD).

Recently, the Mayo Clinic published research on the various types of Alzheimer’s Disease (AD).  Two atypical forms of AD were specifically highlighted — hippocampal sparing (HpSp) and limbic-predominant (LP).  We’ve seen this HpSp type on several neuropathology reports for people who were thought to have CBD and a few for FTD.

Here’s a link to the Mayo research:

ncbi.nlm.nih.gov/pmc/articles/PMC3175379/

Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: A retrospective study

by Melissa E. Murray, PhD, Neill R. Graff-Radford, MBBCh, FRCP (London), Owen A. Ross, PhD, Ronald C. Petersen, MD, Ranjan Duara, MD, and Dennis W. Dickson, MD

Lancet Neurol. 2011 Sep; 10(9): 785–796.
Published online 2011 Jul 27. 

Well worth reading…

Robin

 

Spectrum of Frontotemporal Degeneration – 3/2/11 Webinar Notes

I listened to yesterday’s AFTD (Association for Frontotemporal Degeneration) webinar on the spectrum of frontotemporal degeneration, thinking it was truly about the “spectrum.”  It was NOT about the spectrum in that the speaker announced early on that he would be ignoring PSP and CBS (two movement types of FTD), and concentrating on the three other types of FTDs – bvFTD, PNFA, and SD.  So my notes may not be of much interest to the PSP and CBD communities.

—————-

Notes by Robin Riddle about

The Spectrum of Frontotemporal Degeneration
AFTD webinar
Wednesday, March 2, 2011
Speaker – Mario Mendez, MD, PhD, Director of the FTD and Neurobehavior Clinic, UCLA

Organization of Talk
1. What is frontotemporal degeneration (FTD)?
2. What are the clinical syndromes of FTD?
3. Principles of Management
4. Resources and Referral

Brief History of FTD Syndromes
1892: Arnold Pick described 6 patients with FTD
1911: Alzheimer describes the neuropathology
DARK AGES
1993+: Renaissance: Epidemiology, Clinical Criteria
1997: Age of Tauopathy: FTDP-17, abnormal tau
2006: Age of TDP43 protein and progranulin gene
2009+: NEW AGE OF EXPLORATION, THERAPY

Epidemiology of FTD Syndromes

1. 5-8% of dementias; 13.5-15% if onset < 65
AD, VaD, and DLB are more common than FTD
Second most common dementia among young people

2. Prevalence/Incidence in 45-64 yr age group: 15/100,000 and 1-2/100,000

3. Usual onset in 50’s (mean onset 57-58)
Strikes people in their prime
Devastating time to develop a dementia: raising a family; making an income

4. Slightly more men than women

5. Duration shorter than AD (mean 8 years)
There are different series with different means and members.
Mean duration of about 7.6 years makes the most sense to him.
Semantic Dementia may be longer (9 years).

Three Key Points on FTD

1. Variable phenotypes and syndromes:
Behavioral variant FTD (bvFTD) involves social brain
Progressive nonfluent aphasia (PNFA)
Semantic dementia (SD)
Others: FTD-MND (10%), CBS (asymmetric motor findings; ideomotor apraxia), PSP

CBS and PSP are related syndromes. They are movement disorders. This talk will focus on the main syndromes.

2. Variable neuropathology: misfolded protein. The most common abnormal inclusions (clumps of protein) are with TDP-43 (45%), tau (40%), and FUS.

3. 15% autosomal dominant genetic mutations: in MAPT, PRGN, VCP, FUS, CHMP2B, TARDBP (this last one is with TDP-43).

Variable phenotypes and syndromes: Some people are very frustrated by this!

FTD Common Syndromes:

1. bvFTD: behavioral variant ~ 50%
A. often present with apathy, abulia, or detachment. MDs commonly diagnose these people as depressed when, in fact, these people are developing problems in the frontal lobe. Need to screen for depression.
B. Disinhibition or impulsivity. People violate social boundaries. Causes distress in families. He calls this “Private behaviors in public.”
C. FTD-MND (motor neuron disease)

2. Language predominant variants
A. PNFA: Progressive non-fluent aphasia ~ 25%
B. SD: Semantic dementia ~25%

3. CBS or PSP: parkinsonism symptoms

The FTD Spectrum With 5-Year UCLA FTD Clinic Experience:
FTD (behavioral variant), n=118
Primary Progressive Aphasia (non-fluent), n=48
Semantic Dementia, n=19
Corticobasal syndrome, n=11
Progressive supranuclear palsy, n=9
(Literature: MND in about 15%)

Frontotemporal Degenerations
Frontotemporal Dementia: 56.7%; Age at Onset 57.5 (9.7); Male sex 63.5%; Initial MMSE 22.7 (6.6)
Progressive Nonfluent Aphasia: 18.7%; Age at Onset 59.3 (8.2); Male sex 66.7%; Initial MMSE 21.5 (7.08)
Semantic Dementia: 24.6%; Age at Onset 63.0 (9.7); Male sex 39.1%; Initial MMSE 22.5 (7.0)
From Johnson et al, Arch Neurol 2005;62:925-30

bvFTD – Core diagnostic features
A. Insidious onset and gradual progression
B. Early decline in social interpersonal conduct
C. Early impairment regulation of personal conduct
D. Early emotional blunting: Acting as if they don’t care. Not caring about others.
E. Early loss of insight: No acceptance that anything is wrong.

From: Neary et al, Neurology 1998;51:1546-51;
SE 85%, SP 99% among 34 patients in Knopman et al, 2005

These diagnostic criteria are difficult to operationalize! How do you assess “early decline in social interpersonal conduct”?

Symptoms in 53 bvFTD Patients – at onset and after 2 years:
Decline in social conduct: 39.6% onset; 83% 2 years
Impaired personal regulation: 69.8% onset; 88.7% 2 years
Emotional blunting: 35.8% onset; 94.3% 2 years
Lack of insight: 58.5% onset; 100% 2 years
Compulsive-like behaviors: 45.3% onset; 88.7% 2 years
Logopenia and anomia: 41.5% onset; 96.2% 2 years
Hyperorality (other KBS) 0% onset; 20.8% 2 years

From Mendez & Perryman, 2002

Results of 134 referrals to the UCLA FTD & Neurobehavior Clinic for possible bvFTD:
23 (17.2%) initially met criteria for bvFTD
40 converted to bvFTD by two year f/up
36 had psychiatric disorder
17 had Alzheimer’s disease
9 had another neurological disorder [Anoxic encephalopathy (2), prion disease (2), Hashimoto’s encephalopathy, neurosarcoidosis, NPH, paraneoplasticsyndrome, sleep apnea syndrome] 9 without final diagnosis

Note how few met the criteria for bvFTD!

International Consensus Criteria for bvFTD

I. Neurodegenerative Disease: progressive deterioration behavior and/or cognition

II. Possible bvFTD (3 of A-F present…so 3 out of 6)

A. Early behavioral disinhibition (1 or more)
1. Socially inappropriate behavior
2. Loss of manners or decorum
3. Impulsive, rash or careless actions

B. Early apathy or inertia

C. Early loss of sympathy or empathy (1 or more)
1. Diminished response to others people’s
needs and feelings
2. Diminished social interest, interrelatedness
or personal warmth

D. Early perseverative, stereotyped or compulsive/ritualistic behavior
1. Simple repetitive movements
2. Complex, compulsive or ritualistic
3. Stereotypy of speech

E. Hyperorality and dietary changes (1 or more)
1. Altered food preferences
2. Binge eating, increased consumption of alcohol or cigarettes
3. Oral exploration or consumption of inedible objects

F. Neuropsychological profile (all 3 present)
1. Deficits in executive tasks
2. Relative sparing of episodic memory
3. Relative sparing of visuospatial skills

These are much better. They will be approved soon.

C: has some similarities with autistic spectrum disorders.

The clinical diagnosis should be corroborated with neuro-imaging. Scan shows disproportionate frontal lobe hypometabolism. The imaging is getting better and better.

UCLA uses the FDDNP ligand. FDDNP-PET shows different distribution of cortical pathology in AD and FTD.

The disease often begins in the “social brain.”

How does FTD affect social behavior?
1. Acquired sociopathy (Mendez et al, 2003; Miller et al, 1997)
2. Reduced understanding of social concepts (Zahn et al, 2009)
3. Reduced self-referential emotions (Sturm et al, 2006)
4. Reduced recognition of facial emotions (Rosen et al, 2005)
5. Reduced empathy (cognitive-OF, emotional-TL; Rankin et al, 2005)
6. Reduced theory of mind (Gregory et al, 2002; Lough et al, 2006)
7. Reduced recognition of humanness (Mendez et al, 2005,2006)

Sociopathy in 16 FTD Patients seen at UCLA:
3 Unsolicited sexual approach or touching
3 Traffic violations including hit-and-run accidents
2 Physical assaults
1 Shoplifting
1 Deliberate non-payment of bills
1 Pedophilia
1 Indecent exposure in public
1 Urination in inappropriate public places (eg, on neighbor’s lawn)
1 Stealing food
1 Eating food in grocery store stalls
1 Breaking and entering into others’ homes (eg, in order to play the piano)

Phineas Gage: famous patient; iron rod damaged his frontal lobe. He illustrates the disinhibited subtype.

International Guidelines for the Diagnosis of Primary Progressive Aphasia – Workgroup Results
Three main variants:
• PNFA ­ progressive non-fluent aphasia: Now nonfluent/agrammatic variant PPA
• SD ­ semantic dementia: Now semantic variant PPA
• PLA- progressive logopenic aphasia: Now logopenic variant PP. This is often AD.

Progressive NF Aphasia
• Grammatical difficulty in language production
• Reduced motor speech — effortful, hesitant, phonemic abnormality
• Apraxia of speech frequently present
• Reduced comprehension of syntactically complex sentences
• Spared word comprehension and object recognition
• Atrophy inferior left frontal-anterior insula region

[There were lots of examples of agrammatic speech. See the PDF for all of those.]

Semantic Dementia
• Multimodal semantic deficits (modality-specific)
• Semantic anomia – decreased category fluency & decreased word comprehension
• Abnormal person and object recognition
• Surface dyslexia and regularization, typicalization errors
• Decreased specificity, general (superordinate) word preference
• Bizarre food choices or fads and rigidity
• Atrophy of temp polar, perirhinal “recognition” cortex

He calls this the “what is” disease as patients ask “what is a bottle?,” “what is this?”

Pyramids and palm trees test.
Drawings become more generic. Drawing of peacock becomes more generic.

Logopenic Variant PPA: Not discussing today as this is typically AD.

Evolution of FTD’s (2-5 yrs)
• FTDbv: 1/2 become PNFA; 1/4 become CBS/PSP
• PNFA: 1/2 become FTDbv; 1/3 become CBS/PSP
• CBS/PSP: 1/2 become FTDbv; 1/2 become PNFA
• SD: 3/4 become FTDbv
• Differences still persist at end of life
From Kertesz et al, 2007; Snowden et al, 2007

MAPT and PRGN
• 6% Microtubule-associated tau gene (C’17) mutations
• Progranulingene (C’17) mutations in 10%; TAR-DNA-binding protein-43 (TDP-43) in ubi+ inclusions

Good review in the journal Neurology about genetic testing with genetic counseling.
Most people don’t benefit from genetic testing.
There is genetic testing for MAPT and PRGN.

[There was a slide on CSF biomarkers, different from the slide in the PDF.]

His management approach:
Primarily symptomatic
SSRIs helpful for disinhibition and repetitive or compulsive behaviors
Trazodone for more disruptive behaviors
Methylphenydate useful in activating some who lack initiation or are apathetic
AchI used in AD can make things worse in FTD (disinhibition, repetitive behaviors)

Long list of drugs tested in FTD

Caregiver support is extremely important:
* Behavioral, functional, financial, and legal counseling
* Provide an “external executive”
* Use AFTD (theaftd.org) and Alzheimer’s Association resources
* Speech, occupational, physical therapy
* Establish dedicated support groups
* Daycare, respite care and nursing care

Conclusions
* FTD is common in those <65 who develop changes in social behavior or language
* The clinical syndromes vary and overlap. The main syndromes are bvFTD, PNFA, and SD. Others are FTD-MND, CBS, and PSP.
* The neuropathology varies.
* 15% are genetic and include MAPT, PRGN, FUS, valosin, and TARBP genes. Must provide genetic counseling for the entire family.
* Management is primarily symptomatic. Focus on treating disruptive behaviors with a limited psychoactive agents such as SSRIs.
* Contact AFTD

Questions and Answers:

Q: Is there a standard evaluation?

A: We have standard scales we use, including neuropsychological tests. UCLA has its own MRI sequence or series.

Q: Once diagnosed, do you declare them incapacitated?

A: Yes/No. Capacity is state-dependent. The communication to the patient and family: “the patient is incapacitated.” Patients are more incapacitated than their neuropsychological tests will tell you. The patient is at risk for poor decision-making.

Q: Is there a correlation with traumatic brain injury?

A: TBI is not an established risk factor for FTD.

Many with TBI are injured in their frontal lobes so some of the symptoms may be the same.

Q: Neuropathological differences?

A: [didn’t understand question or answer!]

 

FTD Webinar, Wed 3/2, noon CST, registration open

Editor’s note:  See our notes from the webinar here.

Sorry for the short notice on this. I just received an email on this webinar from the AFTD — which now stands for the Association for Frontotemporal Degeneration (rather than Dementia). The AFTD now has a new web address as well; you can find them online at theaftd.org. (ftd-picks.org re-routes you to theaftd.org.)

You are invited to participate in this webinar:

The Spectrum of Frontotemporal Degeneration
(tomorrow) Wednesday, March 2
noon to 1pm central time
speaker – Dr. Mario Mendez, Director of the FTD and Neurobehavior Clinic at UCLA
register here – http://cme.edocendo.com/

The registration page gives these objectives for the webinar:

“Those attending this presentation will receive information that should allow them to:
– Have a working knowledge of frontotemporal degeneration (FTD) and how to diagnosis these syndromes;
– Comprehend the major clinical syndromes of FTD: bvFTD, PPA, CBS, PSP;
– Learn principles of management of FTD, particularly addressing the unique burden on caregivers and family;
– Know where to find resources and when to refer patients with FTD.”

When you register, you first have to create an account, which requires entering a username and password. Then you fill out a form that asks for your name, last four digits of SSN, your degree, your company, your address, and your phone #. (There is no accuracy-checker.) You are then sent an email which tells you how to join the webinar tomorrow.

This webinar is sponsored by AFTD. Most of the audience will be physicians and other medical professionals. (CME — continuing medical education — credits are available for MDs.)

There’s a short 4-question pre-test on FTD you can take.* Based on that pre-test and other MD-oriented webinars I’ve attended, my guess is that most people here will be able to understand much of what is said.

Robin

—————-

* The Spectrum of Frontotemporal Degeneration Pre-Test

The following test must be completed prior to participating in “The Spectrum of Frontotemporal Degeneration” CME activity. This test is required for you to receive your CME credit.

1. FTD has its usual onset in the elderly (>65 years of age)?
A. True
B. False

2. FTD is clinically indistinguishable from Alzheimer disease?
A. True
B. False

3. The diagnosis of FTD relies on clinical criteria rather than laboratory tests?
A. True
B. False

4. The most common presentations of FTD are personality changes or language problems?
A. True
B. False